.png)
Biobeat
Cuffless wearable patch for continuous BP and multi-vital RPM with AI early-warning
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Biobeat is positioned as a focused med-tech remote patient monitoring company commercializing cuffless blood-pressure and multi-vital-sign wearables, with strong regulatory positioning and apparent expansion into U.S. commercialization after new funding.[1][5][9] Its strategy appears centered on converting proprietary PPG and AI capabilities into clinical adoption across hospitals, home care, and ambulatory monitoring markets.[1][6][9]
Efficiency Ratio
Biobeat appears relatively efficient at turning a small team into a regulated, multi-product clinical platform with FDA-cleared and CE-marked offerings, indicating high output per employee compared with a typical med-tech hardware firm.[1][7][11]
Evidence Signals
Biobeat reportedly raised $50 million in Series B financing in December 2025 to support commercialization of its blood-pressure sensor.
The company markets an FDA-cleared cuffless ambulatory blood pressure monitoring system and wearable chest and wrist monitors for continuous vital-sign monitoring.
Biobeat states its wearable devices are FDA-cleared and CE-mark certified, with HIPAA- and GDPR-compliant cloud monitoring infrastructure.
Biobeat is a member of the Medical Technology Enterprise Consortium (MTEC), indicating participation in an industry and defense-medical ecosystem.
The company claims the world's largest vital-sign database and uses AI-based early warning scoring for deterioration detection.
Public company profiles indicate roughly 38 employees, suggesting a relatively small operating footprint despite a broad clinical product set.
Biobeat reports clinical use across hospitals, clinics, home care, and research settings, with named institutional customers appearing in third-party company summaries.
- About
- Israeli medical-device company (Biobeat Technologies Ltd.; HQ Petah Tikva/Tel Aviv, Israel with operations in Boca Raton, Florida), founded in 2016 by Arik Ben Ishay. Makes wireless, cuffless wearable monitors — a chest patch and a wrist device — that use photoplethysmography (PPG) to track blood pressure, SpO2, pulse, respiration, temperature, and cardiac output/stroke volume, feeding a cloud platform with an AI-based Early Warning Score for patient deterioration. It holds the first-ever FDA clearance for cuffless PPG-only blood pressure, is the first FDA-cleared cuffless 24-hour ambulatory BP monitor (ABPM), and is CE-marked. Raised a $50M Series B (Dec 2025, led by Ally Bridge/OrbiMed/Elevage) to expand US commercialization. Continuous wearable vitals + deterioration scoring map to the casualty-monitoring / prolonged-field-care thread of C12; defense relevance is commercial-first.
- Tags
- #wearable #cuffless #bloodpressure #abpm #ppg #rpm #ews #fda #vitals #patch